DelveInsight

View All

Ketamine to work in mice

Gender matters for Party drug Ketamine to work its anti-depressant activity in mice Experiments involving the popular party drug ketamine, a psychoactive recreational drug used to uplift mood of the user, in mice has deepened the mystery of how the dug affects the brain further. Results of a study conducted at the U...

Find More

BioGen
Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...

Find More

Targeting cancer through CD40 agonists -A promising future

Cluster of differentiation 40 or CD40 is a co-stimulatory protein found on the antigen presenting cells of the immune system. Agonistic CD40 molecules which include monoclonal antibodies (mAb) offer a new therapeutic option with the potential to generate anticancer immunity by various mechanisms. CD40 is a TNF recep...

Find More

Chemists may help solve the air-pollution health crisis

One of the top five risks for human health includes poor air quality, while the others are blood pressure, smoking tobacco, diabetes, and obesity. The poor air quality has contributed to around 8% of deaths around the world, according to a 2015 statistic and long-term exposure has created health hazard risks such as...

Find More

Delveinsight
Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires

Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology ...

Find More

severe combined Immunodeficiency
Bubble Boy Syndrome (ADA-SCID) – A Rare Immunodeficiency Disorder

Severe Combined Immunodeficiency (SCID) is an inherited primary immunodeficiency disease (PIDD) that typically presents in infancy. It is characterized by profound immune deficiency condition resulting in a weak immune system that is unable to fight off even mild infections. Severe Combined Immunodeficiency is a rar...

Find More

Business Cocktail

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle-free drug delivery device and increase patient compliance rates for biologic medicines manufactured by the former compa...

Find More

‘Killer’ Mosquito to be released in 20 US states to fight mosquitoes

'Killer' Mosquito to be released in 20 US states to fight disease-causing mosquitoes The US Environmental Protection Agency (EPA) has approved the use of a common bacterium to kill wild mosquitoes that transmit viruses such as dengue, yellow fever and Zika. The biotechnology start-up MosquitoMate means to release th...

Find More

Notizia
AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung c...

Find More

Wet AMD: A chronic eye condition with promising therapies

Wet AMD is a chronic eye disease that causes blurred vision or a blind spot in a person’s visual field. It is characterized by abnormal blood vessels that leak blood and fluids into the macula, a region of the eye that is responsible for sharp, central vision. Age-related macular degeneration (AMD) is a common eye c...

Find More